Patient-reported outcomes in early phase trials for patients with myelodysplastic syndromes.

Autor:	Mendoza T; Office of Patient-Centered Outcomes Research, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: tito.mendoza@nih.gov., King AL; Office of Patient-Centered Outcomes Research, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Vera E; Office of Patient-Centered Outcomes Research, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Mina A; Myeloid Malignancies Program, Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., McGraw K; Myeloid Malignancies Program, Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Pavletic S; Myeloid Malignancies Program, Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Armstrong TS; Office of Patient-Centered Outcomes Research, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jazyk:	angličtina
Zdroj:	Seminars in hematology [Semin Hematol] 2024 Dec; Vol. 61 (6), pp. 457-464. Date of Electronic Publication: 2024 Oct 30.
DOI:	10.1053/j.seminhematol.2024.10.010
Abstrakt:	Patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) experience a wide range of symptoms due both to their underlying disease and the effects of treatment. Designing early phase trials to explore effective therapies in these patients should not only examine anti-tumor activity, but also consider the effects of treatments on how patients feel and function. Assessing symptomatic toxicities associated with new therapies in early phase trials from the patient perspective is best measured using patient-reported outcomes (PROs) and offers valuable insight and complementary information to the traditional adverse event reporting in cancer clinical trials. This review describes PROs, highlights their importance in MDS drug development, and outlines the key psychometric properties and practical considerations that make PROs essential and desirable in evaluating the impact of new therapies. We will provide a general overview of PROs and follow with application of PROs in MDS/AML including strategies to be considered in early phase trials. Finally, we describe the creation of the Office of Patient-Centered Outcomes Research at the US National Institutes of Health which has developed a standardized PROs methodology for early phase trials conducted in the Center for Cancer Research at the US National Cancer Institute. Competing Interests: Declaration of competing interest None. (Copyright © 2024. Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu